| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Pediatrics [S. L. C.], Pathology [P. M. C.], and the Robert H. Lurie Comprehensive Cancer Center [D. H., A. B.], Northwestern University, Chicago, Illinois 60611, and the Divisions of Oncology [J. L. K., G. M. B.] and Neurology [J. L. R.], The Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania 19104
Neuroblastomas are biologically heterogeneous tumors that consist of two main cell populations: neuroblastic/ganglionic cells and Schwann cells. The amount of Schwannian stroma strongly impacts prognosis, and favorable outcome is associated with tumors that are Schwannian stroma rich/stroma dominant. At the present time, there is controversy regarding the origin of Schwann cells in neuroblastoma tumors. However, recent studies have suggested that the Schwann cells in mature neuroblastoma tumors may be normal cells that produce soluble substances that enhance the survival and differentiation of neuroblastoma cell lines. Previously, we reported that in neuroblastoma, high vascular index correlated with clinically aggressive disease. In contrast, tumors with favorable histology and abundant Schwannian stroma had low tumor vascularity. As a first step toward investigating whether Schwann cells also play a role in inhibiting angiogenesis in neuroblastoma tumors, we examined the ability of conditioned medium collected from normal human Schwann cells to affect basic fibroblast growth factor- and vascular endothelial growth factor-induced endothelial cell proliferation and migration and in vivo angiogenesis. In vitro angiogenesis assays were also performed with conditioned medium collected from Schwann cells derived from a Schwannian stroma-dominant neuroblastoma tumor. Our results indicate that Schwann cells derived from either adult nerve or tumor tissue produce a potent inhibitor(s) of angiogenesis. Expression studies revealed tissue inhibitor of metalloproteinase (TIMP)-2 in conditioned medium collected from both normal and tumor-derived Schwann cells. In addition, TIMP-2 was detected in the cytoplasm of Schwann cells and ganglion cells in stroma-rich/stroma-dominant neuroblastoma tumors by immunohistochemistry studies. We postulate that the low level of vascularity and more benign clinical behavior of Schwannian stroma-rich/stroma-dominant neuroblastoma tumors result from the Schwann cell production of TIMP-2 and/or other inhibitors of angiogenesis.
This article has been cited by other articles:
![]() |
R. Peddinti, R. Zeine, D. Luca, R. Seshadri, A. Chlenski, K. Cole, B. Pawel, H. R. Salwen, J. M. Maris, and S. L. Cohn Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma Clin. Cancer Res., June 15, 2007; 13(12): 3499 - 3506. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yang, Y. Tian, S. Liu, R. Zeine, A. Chlenski, H. R. Salwen, J. Henkin, and S. L. Cohn Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma Cancer Res., February 15, 2007; 67(4): 1716 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, Y. Tian, A. Chlenski, Q. Yang, P. Zage, H. R. Salwen, S. E. Crawford, and S. L. Cohn Cross-Talk between Schwann Cells and Neuroblasts Influences the Biology of Neuroblastoma Xenografts Am. J. Pathol., March 1, 2005; 166(3): 891 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. RIBATTI, D. MARIMPIETRI, F. PASTORINO, C. BRIGNOLE, B. NICO, A. VACCA, and M. PONZONI Angiogenesis in Neuroblastoma Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 133 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chlenski, S. Liu, L. J. Baker, Q. Yang, Y. Tian, H. R. Salwen, and S. L. Cohn Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC Cancer Res., October 15, 2004; 64(20): 7420 - 7425. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-W. Yang, S. Liu, Y. Tian, H. R. Salwen, A. Chlenski, J. Weinstein, and S. L. Cohn Methylation-associated Silencing of the Thrombospondin-1 Gene in Human Neuroblastoma Cancer Res., October 1, 2003; 63(19): 6299 - 6310. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al. SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis Cancer Res., December 15, 2002; 62(24): 7357 - 7363. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Krekoski, D. Neubauer, J. B. Graham, and D. Muir Metalloproteinase-Dependent Predegeneration In Vitro Enhances Axonal Regeneration within Acellular Peripheral Nerve Grafts J. Neurosci., December 1, 2002; 22(23): 10408 - 10415. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Crawford, V. Stellmach, M. Ranalli, X. Huang, L. Huang, O. Volpert, G. H. De Vries, L. P. Abramson, and N. Bouck Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity J. Cell Sci., March 14, 2002; 114(24): 4421 - 4428. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |